| Abstract | BACKGROUND: The goal of this study was to conduct an accelerated vaccination program and to determine its efficacy in patients susceptible to hepatitis B virus (HBV) receiving chemotherapy because of their hematologic malignancies. METHODS: Over a one-year period, a total of 327 patients who were diagnosed as having a hematologic malignancy were serologically analyzed in terms of HBV infection. Of those found to be susceptible to HBV infection, a total of 42 patients consisting of 16 females and 26 males were enrolled in the accelerated vaccination program. All the patients were administered a 20-microg yeast-derived recombinant hepatitis B vaccine on days 0, 14, and 28. Anti-HBs titers above 10IU/l at 1 and 3 months after the final dose were accepted as protective. RESULTS: A total of 146 (44.6%) patients were susceptible to HBV, while 13 (4.0%) were carriers, 28 (8.6%) were vaccinated, and 113 (34.5%) had had a previous HBV infection. A total of 42 patients (16 females and 26 males, mean age 34.5+/-10.9 years) were enrolled in the vaccination program. Overall, 23.8% (10/42) of the patients in the program had developed anti-HBs at one month after the last vaccination. CONCLUSIONS: Poor results obtained by different vaccination programs suggest the need for alternative strategies to prevent the disease. |
| Authors | Husnu Pullukcu, Ekin Ertem, Yildiray Karaca, Tansu Yamazhan, Ruchan Yazan Sertoz, Imre Altuglu
(Affiliation: Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Turkey. husnup at yahoo.com)
|
| Journal | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
(Int J Infect Dis)
Vol. 12
Issue 2
Pg. 166-70
(Mar 2008)
ISSN: 1201-9712 Canada |
| PMID | 17720599
(Publication Type: Comparative Study, Evaluation Studies, Journal Article)
|
| Chemical References |
- Antineoplastic Agents
- Hepatitis B Antibodies
- Hepatitis B Antigens
- Hepatitis B Vaccines
|
| Topics |
- Adolescent
- Adult
- Age Distribution
- Aged
- Antineoplastic Agents
(therapeutic use)
- Female
- Hematologic Neoplasms
(complications, drug therapy)
- Hepatitis B
(immunology, prevention & control)
- Hepatitis B Antibodies
(blood)
- Hepatitis B Antigens
(blood)
- Hepatitis B Vaccines
(administration & dosage, standards)
- Humans
- Immunization Schedule
- Immunoenzyme Techniques
- Male
- Middle Aged
- Sex Distribution
- Vaccination
(methods, standards)
|
